Jong-ho Cha

Associate Professor

Inha University
Country flagSouth Korea

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Jong-ho Cha is an Associate Professor at Inha University, South Korea. His research primarily focuses on immunotherapy, specifically exploring immunogenic cell death, tumor microenvironment remodeling, and macrophage polarization in cancer. Recent publications include works on PD-L1 in therapeutic applications and the use of artificial intelligence for high-throughput screening in immunogenic therapies.

Articles (12)

Year:

2025

Nicotinamide phosphoribosyltransferase (NAMPT) is a metabolic enzyme with key roles in inflammation. Previous studies have examined the consequences of its upregulated expression in cancer cells themselves, but studies are limited with respect to its role in the other cells within the tumor microenvironment (TME) during colorectal cancer (CRC) progression. Using single‐cell RNA sequencing (scRNA‐seq) data, it is founded that NAMPT is highly expressed in SPP1 + tumor‐associated macrophages (TAMs), a unique subset of TAMs associated with immunosuppressive activity. A NAMPT high gene signature in SPP1 + TAMs correlated with worse prognostic outcomes in CRC patients. The effect of Nampt deletion in the myeloid compartment of mice during CRC development is explored. NAMPT deficiency in macrophages resulted in HIF‐1α destabilization, leading to reduction in M2‐like TAM polarization. NAMPT deficiency caused significant decreases in the efferocytosis activity of macrophages, which enhanced STING signaling and the induction of type I IFN‐response genes. Expression of these genes contributed to anti‐tumoral immunity via potentiation of cytotoxic T cell activity in the TME. Overall, these findings suggest that NAMPT‐initiated TAM‐specific genes can be useful in predicting poor CRC patient outcomes; strategies aimed at targeting NAMPT may provide a promising therapeutic approach for building an immunostimulatory TME in CRC progression.

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Collaborators (4)

Ying-Nai Wang

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

You‐Sun Kim

-

SOUTH KOREA
View details

Jae-Seok Roe

Associate Professor

Yonsei University

SOUTH KOREA
View details

Yves SY Hsieh

Associate Professor

Kungliga Tekniska Högskolan

SWEDEN
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.